Global Temporary Pacemaker Market Overview:
Temporary pacemaker (TP) is used in the emergency treatment of a patient with severe Bradyarrhythmia (slow heart rate). The primary factor leading to the growth of this market is the increase in the rate of cardiac diseases. Rising preference of cardiologists for use of Temporary Pacemakers is further fueling the market. Robust health care infrastructure, government funding in developed and developing nations also contribute to the substantial rise in the temporary pacemaker market.
Growth Drivers
- Increased Prevalence of Chronic Heart Failure and Incidence of Acute Heart Failure Worldwide
- Increasing Affordability and Healthcare Access in Developing Countries
Roadblocks
- High Cost of Surgery
- High Risk of Device Malfunction
Opportunities
- Potential Market Growth in Countries with the Highest Rate of Cardiovascular Disorders
- Changing Lifestyle, Increased Consumption of Fats and Sugars Posing Serious Health Risks
- Countries with the Largest Aging Population in the World
Challenges
- Highly Mature Market Makes It Difficult To Penetrate
- Lack of Skilled Professionals in Developed Economies
Competitive Landscape:
Some of the key players profiled in the report are Medtronic (United States), OSCOR Inc (United States), Biotronik Gmbh Co. (Germany), B. Braun Melsungen AG (Germany), Cardiac impulse S.R.L (Italy), Sorin Group (Italy), Biosensors International (Singapore), Instrumentation laboratory SpA (Italy) and Vitatron (The Netherlands). Additionally, following companies can also be profiled that are part of our coverage like Greatbatch (United States), St. Jude Medical (United States), Medico Inc. (United States), Abbott Laboratories (United States), Boston Scientific (United States), Shree Pacetronix Ltd. (India) and Cardiologic Ltd. (United Kingdom). Analyst at AMA Research see United States Players to retain maximum share of Global Temporary Pacemaker market by 2026. Considering Market by End User type, the sub-segment i.e. Arrhythmia and Cardiac Conduction Disorders will boost the Temporary Pacemaker market.
In March 2017, Medtronic announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has approved coverage for the Micra® Transcatheter Pacing System (TPS). It is the first and only Leadless Pacemaker available for use in the United States.
The 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronisation Therapy developed in collaboration with the European Heart Rhythm Association (EHRA), have created a new classification system for bradyarrhythmias according to mechanisms rather than aetiology. The guidelines, presented at the EHRA EUROPACE meeting, in June and published simultaneously in the European Heart Journal and EP Europace, have been redesigned to offer a more accessible format for users. Greater emphasis than ever before has been placed on a practical ‘how-to’ approach targeted at generalists, including GPs and geriatricians, as well as expert cardiologists and electrophysiologists. The new ESC Guidelines take into account whether the patient has a persistent problem, or whether it is intermittent, and whether it has been documented with electrocardiographic evidence (ECG documented) or not (ECG-undocumented).
What Can be Explored with the Temporary Pacemaker Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Temporary Pacemaker Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Temporary Pacemaker
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Temporary Pacemaker market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Temporary Pacemaker market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Keyword Manufacturer, Healthcare Industry, Raw Material Supplier, End-User, Government Bodies and Associations, Research Companies and Traders/Distributors/Suppliers.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.